Skip to content
Home/Companies/Biotech/Transcripta Bio
Transcripta Bio

Transcripta Bio

Biotech·US·Active·6yr hold
Entry
2020
Hold
6yr
Status
Active

Who owns Transcripta Bio?

Transcripta Bio is currently owned by BlueYard Capital through BlueYard Capital Fund II (2019 vintage), since 2020.

Hand-verified · updated 2026-07-17

BlueYard Capital
Investor
BlueYard Capital
BlueYard Capital Fund II · 2019 · VC

Key facts

HQUnited States
SectorBiotech
StatusActive
Websitewww.transcriptabio.com

More from BlueYard Capital Fund II

Other portfolio companies in the same fund.

Dance
Exited 2026
MobilityGermany· 2020
to
Insempra
Active
BiotechGermany· 2020
SEEQC
Seeqc
Active
Deep TechUS· 2020
bit.bio
bit.bio
Active
BiotechUK· 2019
Grid
Grid
Active
SoftwareIceland· 2019
Marvel Fusion
Marvel Fusion
Active
EnergyGermany· 2019

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS
Track Transcripta Bio

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Who could buy Transcripta Bio?

7 strategic and 113financial buyers match this company's sector and geography profile, ranked from verified European deal history.

Find likely buyers

Get the full record on Transcripta Bio.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyers and MOIC on realized deals (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue